The second effect, I said, would be that people (at least those who could afford the drugs) would get thinner overall. Perhaps there would also be a reduction in diabetes numbers and cardiac health ...
The glucagon-like peptide 1 (GLP-1) market is poised for growth due to rising diabetes and obesity rates, expanded therapy options, and a focus on personalized medicine. Innovations in oral GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results